Cyclica is a biotechnology company that leverages AI and computational biophysics to decentralize drug discovery.
The company approaches polypharmacology with a structure-based, AI-augmented in silico discovery platform, centred on Ligand Design and Ligand Express. Powered by MatchMaker™, a proprietary deep learning proteome screening technology, and POEM™, an innovative supervised learning technology for predicting molecular properties, Cyclica’s platform is suited to the design of novel, drug-like chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a team that has deep roots in the industry, a platform, and an innovative decentralized partnership model, Cyclica is creating medicines with precision for unmet patient needs.
Jason Mitakidis and Naheed Kurji founded the biotech company in Toronto, Ontario in 2013.
B2C
26 to 50
Series B
$23,807,896
Scaling Up
2013
Pharmaceuticals
Managed Health Care
Biotechnology
N/A
Driving Drug Discovery
IT and Security
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
N/A
Software
IT Generalist
Toronto, Ontario
Partner Success
Toronto, Ontario
Cloud Security Operations (SecOps)
Toronto, Ontario
Strategic Partnerships Manager
Toronto, Ontario
Associate Computational Scientist (Structural Bioinformatics); Ph.D. or M.Sc.
Toronto, Ontario
AI/ML Professionals
Want to work at Cyclica?
We can introduce you to the right person at Cyclica
Potential Customers
Interested in what they do or partnership?
Learn more about how they work